Literature DB >> 25323335

Benefits of an oxygen reservoir cannula versus a conventional nasal cannula during exercise in hypoxemic COPD patients: a crossover trial.

Rainer Gloeckl1, Inga Heinzelmann, Maximilian Matthaei, Stella Seeberg, Thomas Damisch, Andreas Jerrentrup, Klaus Kenn.   

Abstract

BACKGROUND: The Oxymizer® is a special nasal cannula that provides a higher luminal diameter in combination with an incorporated oxygen (O2) reservoir. It is assumed that a higher O2 concentration can be delivered breath by breath in order to increase oxygenation.
OBJECTIVE: We aimed to investigate the effects of the Oxymizer on endurance time in comparison to a conventional nasal cannula (CNC).
METHODS: Forty-three patients with severe chronic obstructive pulmonary disease (COPD, age 60 ± 9 years, FEV1 37 ± 16% pred.) and indications for LTOT were recruited during pulmonary rehabilitation for this cross-over study. After an initial maximal incremental cycle test, all patients performed 4 cycling endurance time tests at 70% of their peak work rate (twice with the Oxymizer and twice with a CNC, in reverse order).
RESULTS: The endurance time was significantly higher when patients cycled while using the Oxymizer in comparison to while using the CNC [858 ± 754 vs. 766 ± 652 s; between-group difference 92 s (95% confidence interval 32-152), p < 0.001]. In addition to a longer cycling duration, O2 saturation at isotime was significantly higher with the Oxymizer (93.5 ± 5.4 vs. 90.4 ± 5.3%; p = 0.027). Furthermore, there was a positive correlation (r = 0.427, p = 0.002) between the O2 flow rate and improvements in the constant work rate test, showing greater improvements in favor of the Oxymizer in patients with a higher demand for O2 (≥ 4 liters/min).
CONCLUSION: We show that O2 delivery via the Oxymizer is superior to a CNC with regard to endurance capacity and oxygenation during exercise in patients with severe COPD. It seems that patients with a higher demand for O2 (≥ 4 liters/min), in particular, may benefit more from the use of the Oxymizer.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25323335     DOI: 10.1159/000368165

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

1.  Long-Term Oxygen Therapy.

Authors:  Andreas Rembert Koczulla; Tessa Schneeberger; Inga Jarosch; Klaus Kenn; Rainer Gloeckl
Journal:  Dtsch Arztebl Int       Date:  2018-12-24       Impact factor: 5.594

2.  A randomized cross-over trial on the direct effects of oxygen supplementation therapy using different devices on cycle endurance in hypoxemic patients with Interstitial Lung Disease.

Authors:  Anne Edvardsen; Inga Jarosch; Anita Grongstad; Laura Wiegand; Rainer Gloeckl; Klaus Kenn; Martijn A Spruit
Journal:  PLoS One       Date:  2018-12-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.